JOURNAL ARTICLE

Tixagevimab/cilgavimab for the prevention of COVID-19 in vaccine-refractory patients with autoimmune diseases: a prospective cohort study.

  • Published In: Rheumatology, 2024, v. 63, n. 5. P. 1377 1 of 3

  • Database: Academic Search Ultimate 2 of 3

  • Authored By: Minopoulou, Ioanna; Tascilar, Koray; Corte, Giulia; Mutlu, Melek Yalcin; Schmidt, Katja; Bohr, Daniela; Hartmann, Fabian; Manger, Karin; Manger, Bernhard; Korn, Klaus; Kleyer, Arnd; Simon, David; Harrer, Thomas; Schett, Georg; Fagni, Filippo 3 of 3

Abstract

This article investigates the effects of passive immunization with the monoclonal antibody combination tixagevimab/cilgavimab on humoral immune responses and COVID-19 outcomes in high-risk, vaccine-refractory patients with immune-mediated inflammatory diseases (IMIDs). In a prospective cohort study, 38 such patients receiving a single dose of tixagevimab/cilgavimab showed rapid induction and sustained serum and salivary anti-SARS-CoV-2 IgG antibodies for up to six months, with no severe COVID-19 cases observed. Compared to 114 untreated high-risk IMID controls and the general population, the treated group had a lower standardized incidence ratio (SIR) of COVID-19, suggesting potential protective effects of this passive immunization strategy. The study highlights tixagevimab/cilgavimab as a safe and effective preventive option for vaccine-refractory IMID patients, while noting limitations including small sample size and evolving viral variants that may affect antibody efficacy.

Additional Information

  • Source:Rheumatology. 2024/05, Vol. 63, Issue 5, p1377
  • Document Type:Article
  • Subject Area:Law
  • Publication Date:2024
  • ISSN:1462-0324
  • DOI:10.1093/rheumatology/kead391
  • Accession Number:177017016
  • Copyright Statement:Copyright of Rheumatology is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Looking to go deeper into this topic? Look for more articles on EBSCOhost.